Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Cash from Operations: 2009-2025

Historic Cash from Operations for Gyre Therapeutics (GYRE) over the last 16 years, with Sep 2025 value amounting to $4.6 million.

  • Gyre Therapeutics' Cash from Operations rose 168.54% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 56.52%. This contributed to the annual value of -$3.6 million for FY2024, which is 114.06% down from last year.
  • Latest data reveals that Gyre Therapeutics reported Cash from Operations of $4.6 million as of Q3 2025, which was up 117.71% from $2.1 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Cash from Operations registered a high of $42.3 million during Q4 2022, and its lowest value of -$24.4 million during Q1 2021.
  • For the 3-year period, Gyre Therapeutics' Cash from Operations averaged around $2.6 million, with its median value being $2.9 million (2024).
  • Per our database at Business Quant, Gyre Therapeutics' Cash from Operations crashed by 408.48% in 2021 and then soared by 339.30% in 2022.
  • Over the past 5 years, Gyre Therapeutics' Cash from Operations (Quarterly) stood at -$17.7 million in 2021, then spiked by 339.30% to $42.3 million in 2022, then tumbled by 92.06% to $3.4 million in 2023, then crashed by 182.08% to -$2.8 million in 2024, then surged by 168.54% to $4.6 million in 2025.
  • Its last three reported values are $4.6 million in Q3 2025, $2.1 million for Q2 2025, and -$129,000 during Q1 2025.